Media Articles
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 2024
Jul 22 2024: Oxford BioTherapeutics has been named 'Tech SME of The Year' at the Thames Valley Tech & Innovation Awards 2024. The award recognises exceptional use of technology to advance company objectives, improve communities and/or empower clients and celebrates outstanding people and businesses driving progress in the Thames Valley. OBT received the award for its ongoing efforts and application of cutting-edge technology approaches – including the launch of its enhanced proprietary OGAP®-Verify, mass spectrometry and analytical biochemistry – in order to develop new therapeutics to treat unmet needs in cancer.
James Cowper Kreston wrote, “This year's winner, Oxford BioTherapeutics, is an innovative SME at the forefront of bioscience and drug development. Their groundbreaking work is driving the development of life-saving therapies with the potential to help millions live longer, healthier lives while providing fulfilling employment opportunities for some of the country's brightest scientists.”
View the full article published in the Business Magazine here.
Jul 22 2024: Oxford BioTherapeutics has been named 'Tech SME of The Year' at the Thames Valley Tech & Innovation Awards 2024. The award recognises exceptional use of technology to advance company objectives, improve communities and/or empower clients and celebrates outstanding people and businesses driving progress in the Thames Valley. OBT received the award for its ongoing efforts and application of cutting-edge technology approaches – including the launch of its enhanced proprietary OGAP®-Verify, mass spectrometry and analytical biochemistry – in order to develop new therapeutics to treat unmet needs in cancer.
James Cowper Kreston wrote, “This year's winner, Oxford BioTherapeutics, is an innovative SME at the forefront of bioscience and drug development. Their groundbreaking work is driving the development of life-saving therapies with the potential to help millions live longer, healthier lives while providing fulfilling employment opportunities for some of the country's brightest scientists.”
View the full article published in the Business Magazine here.
|
|
|
|
|
FDA grants Fast Track Designation to Boehringer Ingleheim antitumor agent, BI 764532, partnered with Oxford BioTherapeutics
Oct 04 2023: BI 764532 is a novel, investigational DLL3/CD3 IgG-like T-cell engager designed to redirect T cells toward DLL3 protein expressed by cancer cells. In preclinical trials, the agent showed robust antitumor activity against DLL3-positive cells and xenograft models. In October 2023, the FDA granted a fast track designation to BI 764532 as an option for patients with extensive-stage small cel lung cancer (ES-SCLC) that has progressed after at least 2 prior lines of treatment, including platinum-based chemotherapy, and for patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma (epNEC) whose disease has progressed following at least 1 prior line of treatment including platinum-based chemotherapy.
BI 764532 was evaluated as part of a phase 1 trial (NCT04429087) among patients with DLL3-positive SCLC and NEC. Findings from the study were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
The discovery of BI 764532 was enabled through a successful partnership between Oxford BioTherapeutics and Boehringer Ingelheim, initiated in 2013, leveraging OBT’s proprietary OGAP® drug discovery platform for identification of the DLL3 antigen and Boehringer Ingelheim’s longstanding expertise in oncology and development of biotherapeutics
View the full article published in Targeted Oncology here.
View the full article published in Cancer Network here.
Oct 04 2023: BI 764532 is a novel, investigational DLL3/CD3 IgG-like T-cell engager designed to redirect T cells toward DLL3 protein expressed by cancer cells. In preclinical trials, the agent showed robust antitumor activity against DLL3-positive cells and xenograft models. In October 2023, the FDA granted a fast track designation to BI 764532 as an option for patients with extensive-stage small cel lung cancer (ES-SCLC) that has progressed after at least 2 prior lines of treatment, including platinum-based chemotherapy, and for patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma (epNEC) whose disease has progressed following at least 1 prior line of treatment including platinum-based chemotherapy.
BI 764532 was evaluated as part of a phase 1 trial (NCT04429087) among patients with DLL3-positive SCLC and NEC. Findings from the study were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
The discovery of BI 764532 was enabled through a successful partnership between Oxford BioTherapeutics and Boehringer Ingelheim, initiated in 2013, leveraging OBT’s proprietary OGAP® drug discovery platform for identification of the DLL3 antigen and Boehringer Ingelheim’s longstanding expertise in oncology and development of biotherapeutics
View the full article published in Targeted Oncology here.
View the full article published in Cancer Network here.
Oxford BioTherapeutics brings Phase Ib trial with OBT-076 to Europe
Jul 05 2023: Oxford BioTherapeutics expanded its US-based trial investigating OBT-076 as monotherapy and combination treatment to European sites. The trial is investigating OBT-076 in combination with Agenus’ anti-PD1 checkpoint inhibitor (CPI) balstilimab. The combination trial will enrol patients who are CPI-naïve and resistant patients with advanced solid tumours, including lung, gastric and ovarian cancers. Alongside the combination trial expansion, Oxford BioTherapeutics is also extending the monotherapy cohorts into European sites. Both monotherapy and combination expansions will enrol approximately 150 patients in France, Belgium, and Greece. Oxford BioTherapeutics is also adding new sites in the US.
View the full article here.
Jul 05 2023: Oxford BioTherapeutics expanded its US-based trial investigating OBT-076 as monotherapy and combination treatment to European sites. The trial is investigating OBT-076 in combination with Agenus’ anti-PD1 checkpoint inhibitor (CPI) balstilimab. The combination trial will enrol patients who are CPI-naïve and resistant patients with advanced solid tumours, including lung, gastric and ovarian cancers. Alongside the combination trial expansion, Oxford BioTherapeutics is also extending the monotherapy cohorts into European sites. Both monotherapy and combination expansions will enrol approximately 150 patients in France, Belgium, and Greece. Oxford BioTherapeutics is also adding new sites in the US.
View the full article here.
Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data
May 25 2023: OBT's extension of its second collaboration with BI, for an additional two years, as well as adding further programs into the existing collaboration, was featured in Endpoints News. April 2023 marked ten years of OBT's partnership with BI, since then BI has selected three targets discovered using OBT's proprietary OGAP platform with two leading to candidates in Phase I.
View the full article here.
May 25 2023: OBT's extension of its second collaboration with BI, for an additional two years, as well as adding further programs into the existing collaboration, was featured in Endpoints News. April 2023 marked ten years of OBT's partnership with BI, since then BI has selected three targets discovered using OBT's proprietary OGAP platform with two leading to candidates in Phase I.
View the full article here.
The ABCs of ADC Potential
April 26 2023: In an interview with the Medicine Maker, CEO Christian Rohlff discusses how OBT leverages the potential of ADCs to develop exciting new treatment modalities as well as their growing market share: "Another major trend is the convergence between ADCs and immunotherapies. As we understand more about immuno-suppressive cells in the tumor microenvironment, it may allow us to harness the dual targeting of cancer cells and immuno-suppressive cells to develop innovative treatments for cancer. ADCs could potentially be used to re-engage and reactivate a patient’s immune system, thereby “priming” a patient for immunotherapy. Bringing these therapies together could improve the treatment landscape for both kinds of medicines."
This article is taken from the Medicine Maker 26 April 2023. View the full article here.
April 26 2023: In an interview with the Medicine Maker, CEO Christian Rohlff discusses how OBT leverages the potential of ADCs to develop exciting new treatment modalities as well as their growing market share: "Another major trend is the convergence between ADCs and immunotherapies. As we understand more about immuno-suppressive cells in the tumor microenvironment, it may allow us to harness the dual targeting of cancer cells and immuno-suppressive cells to develop innovative treatments for cancer. ADCs could potentially be used to re-engage and reactivate a patient’s immune system, thereby “priming” a patient for immunotherapy. Bringing these therapies together could improve the treatment landscape for both kinds of medicines."
This article is taken from the Medicine Maker 26 April 2023. View the full article here.
OBT Declared a “Well-deserved Double Award Winner” at the Fourth Annual Thames Valley SME Growth 100 Awards
March 01 2023: OBT has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards. These awards celebrate the region's most active small and medium-sized enterprises (SMEs) that have grown significantly in the past year. OBT was declared a double-award winner in recognition of its successful growth in 2022, which saw the company double both its turnover and headcount, and apply these additional resources to establish new R&D and clinical partnerships with major players in the international biotechnology space while simultaneously strengthening and extending its drug development pipeline.
This article is taken from the Business Magazine 01 March 2023. View the full press release here.
March 01 2023: OBT has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards. These awards celebrate the region's most active small and medium-sized enterprises (SMEs) that have grown significantly in the past year. OBT was declared a double-award winner in recognition of its successful growth in 2022, which saw the company double both its turnover and headcount, and apply these additional resources to establish new R&D and clinical partnerships with major players in the international biotechnology space while simultaneously strengthening and extending its drug development pipeline.
This article is taken from the Business Magazine 01 March 2023. View the full press release here.
|
|
|
OBT Tops the Thames Valley SME 100 Growth Index 2022
September 28 2022: The annual Thames Valley SME Growth 100 index recognises and promotes the region’s high-growth small and medium-sized enterprises, and is ranked by year on year growth. Independent, privately-owned companies, headquartered in the region, that have grown their turnover significantly in the past year are included. We are pleased that OBT has topped the 2022 index with our substantial growth of 154.5%.
This article is taken from the Business Magazine 28 September 2022.
September 28 2022: The annual Thames Valley SME Growth 100 index recognises and promotes the region’s high-growth small and medium-sized enterprises, and is ranked by year on year growth. Independent, privately-owned companies, headquartered in the region, that have grown their turnover significantly in the past year are included. We are pleased that OBT has topped the 2022 index with our substantial growth of 154.5%.
This article is taken from the Business Magazine 28 September 2022.
How Immune Priming Could Make More Patients Eligible for Immunotherapy
September 14 2022: “Targeting CD205-expressing cells may not only remove cancer cells, but also allow the immune system to reset and restart in an immunogenic direction by selectively depleting regulatory cells, and preventing T cell activation and proliferation."
Read more here about how OBT is developing a dual action antibody-drug conjugate (ADC), targeting the CD205 protein on a) cancer immune inhibitory cells to reverse immune suppression, and b) the cancer cells directly.
This article is taken from European Biopharmaceutical Review October 2022, pages 78-80. © Samedan Ltd.
September 14 2022: “Targeting CD205-expressing cells may not only remove cancer cells, but also allow the immune system to reset and restart in an immunogenic direction by selectively depleting regulatory cells, and preventing T cell activation and proliferation."
Read more here about how OBT is developing a dual action antibody-drug conjugate (ADC), targeting the CD205 protein on a) cancer immune inhibitory cells to reverse immune suppression, and b) the cancer cells directly.
This article is taken from European Biopharmaceutical Review October 2022, pages 78-80. © Samedan Ltd.
Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.